REVER3BAB: AN INNOVATIVE BIOLOGICAL MEDICINE FOR REVERTIRE THE RESISTANCE TO CONVENTIONAL CANCER TREATMENT (Q2035362): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item) |
(Changed an Item: Label in wikidata changed) |
||
label / en | label / en | ||
REVER3BAB: AN INNOVATIVE BIOLOGICAL MEDICINE FOR REVERTIRE THE RESISTANCE TO CONVENTIONAL CANCER TREATMENT |
Revision as of 10:10, 17 March 2020
Project in Italy financed by DG Regio
Language | Label | Description | Also known as |
---|---|---|---|
English | REVER3BAB: AN INNOVATIVE BIOLOGICAL MEDICINE FOR REVERTIRE THE RESISTANCE TO CONVENTIONAL CANCER TREATMENT |
Project in Italy financed by DG Regio |
Statements
423,871.16 Euro
0 references
847,742.32 Euro
0 references
50.0 percent
0 references
13 December 2016
0 references
6 July 2019
0 references
ISTITUTI FISIOTERAPICI OSPITALIERI - IFO
0 references
TAKIS SRL
0 references
ISTITUTO BIOCHIMICO ITALIANO G. LORENZINI
0 references
REVER3MAB: UN ANTICORPO MONOCLONALE DIRETTO CONTRO LA PROTEINA ERBB3 IN GRADO DI BLOCCARE LA PROLIFERAZIONE DELLE CELLULE TUMORALI IN VITRO E IN VIVO, CON POTENZIALE USO COME AGENTE TERAPEUTICO IN CLINICA. (Italian)
0 references
Identifiers
F87H18000370007
0 references